Science Corporation Implants Vision Chip in Stargardt Patient

Science Corporation has reached a significant milestone in neurotechnology and medical innovation. Max Hodak, the chief executive officer and former co-founder of Neuralink, announced that the company successfully implanted its vision-restoring chip, known as PRIMA, into its very first patient diagnosed with Stargardt disease. This breakthrough was detailed during a prominent appearance at TechCrunch Disrupt, where Hodak shed light on how the technology represents a major step forward in the practical application of brain-computer interfaces.

The clinical milestone occurred in May at the Sydney Eye Hospital in Australia, where the patient underwent a specialized one-hour surgical procedure. During the operation, a tiny microchip measuring just a few millimeters was placed beneath the retina at the back of the eye, directly targeting the region where photoreceptor cells had degenerated. The early results from the ongoing trial have shown incredible promise. In the patient's very first rehabilitation session, they were able to discern a single letter, and by the second session, they successfully read a complete word using the device.

To understand the significance of this treatment, it is helpful to look at Stargardt disease itself. It is a rare, inherited genetic eye disorder that progressively destroys central vision while typically leaving peripheral vision intact. The disease attacks the outer retina, leading to the gradual death of light-sensing cells that normally capture visual information. Because the inner retina and the optic nerve often remain healthy, researchers recognized an opportunity to artificially stimulate the remaining neural pathways to restore functional sight to affected individuals.

The mechanics behind the PRIMA system are both elegant and sophisticated. Patients wear a pair of specially designed glasses equipped with a miniature video camera. This camera captures the visual environment in real-time and projects infrared light patterns onto the implanted microchip at the back of the eye. The chip acts as a set of artificial photoreceptors, converting the light signal into electrical impulses. These electrical signals travel down the optic nerve to the brain, which interprets them as meaningful visual information.

While the PRIMA device has already seen commercial availability in parts of Europe for individuals suffering from geographic atrophy, an advanced form of age-related macular degeneration, expanding its use to Stargardt disease marks a bold new frontier. Stargardt disease currently has no known cure, and it affects roughly 150,000 people globally, creating a devastating central blind spot that expands over time. By proving that the technology can help patients with this specific condition, Science Corporation opens the door to treating a broader range of neurodegenerative and ophthalmological disorders.

During his presentation at TechCrunch Disrupt, Hodak emphasized that the broader mission of Science Corporation is to view the central nervous system as an interconnected network. He noted that the retina is fundamentally an extension of the central nervous system, making retinal prostheses, cochlear implants, and motor prostheses part of the exact same technological family of brain-computer interfaces. By shifting the conversation away from computers and toward diverse medical applications, the company is redefining what neural technology can achieve for patients worldwide.